%0 Journal Article %A A Madrid Paredes %A R López Sepúlveda %A E Puerta García %A N Martínez Casanova %A B Cancela Díez %A MA Calleja Hernández %T DGI-026 Drug Use in Patients with Metastatic Breast Cancer %D 2013 %R 10.1136/ejhpharm-2013-000276.292 %J European Journal of Hospital Pharmacy: Science and Practice %P A104-A105 %V 20 %N Suppl 1 %X Background The historic poor prognosis and survival of metastatic breast cancer (MBC) patients has been improved in the last decades by the introduction of multimodal treatment. Purpose To analyse the MBC population and describe the prescription profile used. Materials and Methods We conducted a retrospective observational study. We included all patients with MBC in 2007. Using the digital history, sociodemographic variables (age, sex), clinical (histologic type, oestrogen receptor, ER, progesterone receptor, PR, human epidermal growth factor receptor 2, HER-2, progression from primary tumour, appearance and location of metastases, lymph node involvement, survival, deceased) and therapeutic histories (radiotherapy, hormone therapy, chemotherapy) were collected. Results We included 43 patients with a mean age of 54.5 years (100% female). The most common histological types were infiltrating ductal (60%) and lobular (24.4%) tumours. ER and PR were positive in 75.6% and 50%, respectively. Overexpression of Her-2 was negative in 73.7%. 69.2% of patients with MBC had progressed from primary tumour. The metastization appeared at an average of 44.1 months since diagnosis. The most common sites of metastases were bone (34.06%), lung (16.48%) and liver (20.86%). 93.9% of patients had lymph node involvement and 77.6% were in the terminal phase. 95.3% of patients had received radiotherapy. Endocrine therapy used was fulvestrant (22.97%), anastrozole (21.62%), tamoxifen (20.27%). All patients received chemotherapy, the most used first-line schemes being: epirubicin/cyclophosphamide/docetaxel (30.6%), cyclophosphamide/epirubicin/fluorouracil (20.4%) and cyclophosphamide/methotrexate/fluorouracil (16.6%) in combination with trastuzumab or not. In successive lines, combinations of vinorelbine, docetaxel, capecitabine, carboplatin, gemcitabine were prescribed. Lapatinib and bevacizumab were used from the fourth-line treatment. Conclusions Radiotherapy, not indicated in MBC, was used in early stages of the disease. Due to the variability of patients, treatment regimens are diverse and a predefined schema is not appropriate. Bevacizumab and lapatinib were used in late-stage treatment in patients who had not responded to standard treatment. No conflict of interest. %U https://ejhp.bmj.com/content/ejhpharm/20/Suppl_1/A104.2.full.pdf